Defining certainty of net benefit: a GRADE concept paper
暂无分享,去创建一个
G. Guyatt | P. Oettgen | H. Schünemann | I. Kunnamo | A. Iorio | M. Murad | A. Qaseem | M. Ansari | M. Hultcrantz | J. Meerpohl | B. Alper | H. Schünemann | Joerg J. Meerpohl | M. H. Murad | A. Iorio | Brian S. Alper | Mohammed T. Ansari
[1] Catriona Dutreuilh,et al. Introduction , 2019 .
[2] Gordon H. Guyatt,et al. GRADE Guidelines: 19. Assessing the certainty of evidence in the importance of outcomes or values and preferences-Risk of bias and indirectness. , 2018, Journal of clinical epidemiology.
[3] F. Godlee,et al. Better together: patient partnership in medical journals , 2018, British Medical Journal.
[4] C. Bombardier,et al. A Bayesian model that jointly considers comparative effectiveness research and patients' preferences may help inform GRADE recommendations: an application to rheumatoid arthritis treatment recommendations. , 2018, Journal of clinical epidemiology.
[5] Tracy A Wolff,et al. Update on the Methods of the U.S. Preventive Services Task Force: Methods for Understanding Certainty and Net Benefit When Making Recommendations. , 2018, American journal of preventive medicine.
[6] Gerasimos S Filippatos,et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. , 2017, Journal of the American College of Cardiology.
[7] Mohammed T Ansari,et al. The GRADE Working Group clarifies the construct of certainty of evidence. , 2017, Journal of clinical epidemiology.
[8] M. Singer,et al. Effect of Conservative vs Conventional Oxygen Therapy on Mortality Among Patients in an Intensive Care Unit: The Oxygen-ICU Randomized Clinical Trial. , 2016, JAMA.
[9] H. Schünemann. Interpreting GRADE's levels of certainty or quality of the evidence: GRADE for statisticians, considering review information size or less emphasis on imprecision? , 2016, Journal of clinical epidemiology.
[10] Tianjing Li,et al. Evidence selection for a prescription drug's benefit-harm assessment: challenges and recommendations. , 2016, Journal of clinical epidemiology.
[11] G. Guyatt,et al. Longer- Versus Shorter-Duration Dual-Antiplatelet Therapy After Drug-Eluting Stent Placement , 2015, Annals of Internal Medicine.
[12] Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction , 2015 .
[13] Akshay S. Desai,et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. , 2014, The New England journal of medicine.
[14] David Rind,et al. GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation's direction and strength. , 2013, Journal of clinical epidemiology.
[15] Harlan M Krumholz,et al. Relationship between hospital readmission and mortality rates for patients hospitalized with acute myocardial infarction, heart failure, or pneumonia. , 2013, JAMA.
[16] G. Guyatt,et al. Patient values and preferences in decision making for antithrombotic therapy: a systematic review: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.
[17] Laura Mauri,et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. , 2011, Circulation.
[18] Howard Balshem,et al. GRADE guidelines: 3. Rating the quality of evidence. , 2011, Journal of clinical epidemiology.
[19] H. Schünemann. Guidelines 2.0: Do No Net Harm—The Future of Practice Guideline Development in Asthma and Other Diseases , 2011, Current allergy and asthma reports.
[20] Michael Böhm,et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study , 2010, The Lancet.
[21] R. Ferrari,et al. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial , 2008, The Lancet.
[22] G. Guyatt,et al. Going from evidence to recommendations , 2008, BMJ : British Medical Journal.
[23] Diana Petitti,et al. Update on the Methods of the U.S. Preventive Services Task Force: Estimating Certainty and Magnitude of Net Benefit , 2007, Annals of Internal Medicine.
[24] Cedric M. Smith,et al. Origin and Uses of Primum Non Nocere—Above All, Do No Harm! , 2005, Journal of clinical pharmacology.
[25] G. Guyatt,et al. Grading quality of evidence and strength of recommendations , 2004, BMJ : British Medical Journal.
[26] David R. Jones,et al. An introduction to bayesian methods in health technology assessment , 1999, BMJ.
[27] R. Tibshirani,et al. An Introduction to the Bootstrap , 1995 .